StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Genmab A/S Collaboration Profit-Sharing Revenue by Quarter

Collaboration Profit-Sharing Revenue (Pfizer Tivdak U.S.) ($M)

Genmab A/S Collaboration Profit-Sharing Revenue: $17M in Q3 2026, unchanged from a year earlier.

Latest, Q3 2026
17
Period ended Sep 30, 2026
Change on a year earlier
0.0%
17 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“|| Collaboration revenue | 17 | 17 | 53 | 54”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

Genmab's 50% share of U.S. Tivdak net profits commercialized with Pfizer; Note 3 also includes $10M one-off license revenue in Q3 2026 alongside reimbursement and milestones below.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up collaboration Profit-Sharing Revenue

Cite this data

StockData. (2026). Genmab A/S Collaboration Profit-Sharing Revenue ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/rev-collaboration

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?